The market for Plasma Fractionation Market is expected to reach USD$ 33,386.6 Mn in 2026.
The plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2018 to 2026, from US$ 18,099.5 million in 2017 to US$ 33,386.6 million by 2026. Plasma fractionation is utilized for obtaining large quantities of purified protein from human plasma. Researchers have been focusing diligently on understanding the role and significance of plasma-derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market's growth.
Immunoglobulins are the market's dominant product segment in plasma fractionation. Technical innovations in deriving highly purified proteins from human plasma and the rising prevalence of autoimmune disorders drive the immunoglobulin market's growth. They are primarily composed of five classes (D, G, M, A, and E) and several subclasses that are responsible for immune system consolidation. Albumin is gaining huge attention among researchers owing to its drug-binding properties and its effective use as a formulating drug agent, medical device coating, surgery sealant, and vaccine ingredient.
According to the World Health Organization (WHO), approximately 450 million people are reported to be suffering from mental illness each year. Neurology is dominating the application segment for the plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and the lack of effective biological treatment for neurological disorders. Recently, newer antibodies have been developed to hinder the process of protein cluster misfolding, which causes Alzheimer's and Parkinson's diseases. Immunology applications will be the fastest-growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancements in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.
North America is the supreme leader in the global plasma fractionation market, representing 38% of its share. The dominance is attributed to major factors such as the increasing number of patients suffering from chronic diseases and the presence of state-of-the-art healthcare infrastructure. As per the statistics provided by the Centers for Disease Control and Prevention (CDC), 1 in every 6 Americans is living with a chronic disease.
Europe holds a 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, and Grifols S.A. and the supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% of the market's share and will showcase impressive growth during the forecast period on account of a rise in per capita income and an affordable reimbursement scenario for plasma fractionation products utilized during the treatment of chronic ailments.
This research report presents the analysis of each segment from 2016 to 2026,considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
The market is segmented by product, application, and geography.
Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG, CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG, Sanquin, and Shire, Plc.
The market for Plasma Fractionation Market is expected to reach USD$ 33,386.6 Mn in 2026.
The Plasma Fractionation Market is expected to see significant CAGR growth over the coming years, at 7.1%
The report is forecasted from 2018 -2026.
The base year of this report is 2017.
Biotest AG, CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG are some of the major players in the global market.